Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|E5103||ECOG||A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|E2603||ECOG||A Double-blind; Randomized; Placebo-Controlled Phase III Trial of Carboplatin; Paclitaxel and Sorafenib Versus Carboplatin; Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma||Adult CIRB - Late Phase Emphasis||Available to Open|
|UAZ2016-08-02||CLO-University of Arizona||A feasibility trial of alternating intravaginal application of 5-fluorouracil and imiquimod for treatment of high-grade cervical squamous intraepithelial lesions||Cancer Prevention and Control CIRB||Available to Open|
|ADVL1712||COG||A Feasibility Trial of MLN4924 (Pevonedistat, TAK 924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome||Pediatric CIRB||Available to Open|
|S1619||SWOG||A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma||Adult CIRB - Late Phase Emphasis||Available to Open|
|GOG-0241||GOG||A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865; IND #113912) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)||Adult CIRB - Late Phase Emphasis||Completed|
|ACCL05C1||COG||A Group-Wide; Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy||Pediatric CIRB||Completed|
|AALL15P1||COG||A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND#TBD; NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A Gene Rearrangement||Pediatric CIRB||Available to Open|
|LungMAP||SWOG||A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|S1900A||SWOG||A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (LungMAP Screening Study)||Adult CIRB - Late Phase Emphasis||Available to Open|